Inventor
FANSLOW III WILLIAM C
US32 patents
⚠️ This page may combine multiple inventors who share the name “FANSLOW III WILLIAM C”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
IMMUNEX CORP
23 patentsUS6413932B1Jul 2, 2002
Tek antagonists comprising soluble tek extracellular binding domain
IMMUNEX CORP176 citations99
US5674492AOct 7, 1997
Method of preventing or treating disease characterized by neoplastic cells expressing CD40
IMMUNEX CORP126 citations98
US5457035AOct 10, 1995
Cytokine which is a ligand for OX40
IMMUNEX CORP331 citations98
US5565321AOct 15, 1996
Detection of mutations in a CD40 ligand gene
IMMUNEX CORP56 citations96
US6653447B1Nov 25, 2003
ULBP DNA and polypeptides
IMMUNEX CORP25 citations95
US7405270B2Jul 29, 2008
CD40-Ligand lacking native-pattern glycosylation
IMMUNEX CORP32 citations92
US6521424B2Feb 18, 2003
Recombinant expression of Tek antagonists
IMMUNEX CORP37 citations92
US5900238AMay 4, 1999
Vaccine delivery system
IMMUNEX CORP56 citations92
US7807796B2Oct 5, 2010
ULBP antibodies
IMMUNEX CORP19 citations91
US7495086B2Feb 24, 2009
TWEAK receptor
IMMUNEX CORP17 citations91
US7427669B2Sep 23, 2008
ULBP antibodies
IMMUNEX CORP19 citations91
US7193058B2Mar 20, 2007
ULBP antibodies
IMMUNEX CORP21 citations91
US7067475B2Jun 27, 2006
Tek antagonists
IMMUNEX CORP33 citations91
US6458350B1Oct 1, 2002
ULBP DNA and polypeptides
IMMUNEX CORP18 citations91
US7074408B2Jul 11, 2006
Use of integrin antagonists to inhibit angiogenesis
IMMUNEX CORP49 citations90
US7175849B2Feb 13, 2007
Nectin polypeptides
IMMUNEX CORP18 citations86
US7829675B2Nov 9, 2010
TWEAK receptor
IMMUNEX CORP8 citations82
US5783665AJul 21, 1998
Cytokine which is a ligand for OX40
IMMUNEX CORP14 citations73
US6106832AAug 22, 2000
Treatment of individuals exhibiting defective CD40L
IMMUNEX CORP12 citations72
US6762030B2Jul 13, 2004
Ligand for CD7 and methods for use thereof
IMMUNEX CORP1 citations52
US6774224B2Aug 10, 2004
ULBP DNA and polypeptides
IMMUNEX CORP0 citations51
US6613320B1Sep 2, 2003
Defective CD4+T-cells that express active CD40-L
IMMUNEX CORP0 citations48
US7833697B2Nov 16, 2010
Endothelial stem cells, populations, methods of isolation and use thereof
IMMUNEX CORP0 citations45
AMGEN INC
6 patentsUS9243058B2Jan 26, 2016
BCMA antigen binding proteins
AMGEN INC83 citations96
US7449555B2Nov 11, 2008
Antibodies of angiogenesis inhibiting domains CD148
AMGEN INC20 citations88
US10220090B2Mar 5, 2019
BCMA Antigen binding proteins
AMGEN INC15 citations84
US10465009B2Nov 5, 2019
BCMA antigen binding proteins
AMGEN INC9 citations81
US9574008B2Feb 21, 2017
CD27L antigen binding proteins
AMGEN INC4 citations72
US11427627B2Aug 30, 2022
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
AMGEN INC2 citations69